Pfizer Biontech Covid 19 Vaccine

Covid vaccine makers BioNTech and Pfizer said Wednesday they would produce their jab in South Africa from 2022, a first for the continent that could see much-needed immunisation drives pick up speed.

Pfizer/BioNTech's coronavirus vaccine offers more protection than earlier thought with effectiveness in preventing symptomatic disease reaching 97 percent, according to real-world evidence published Thursday by the pharmaceutical companies.

Britain has used an emergency approval process to jump ahead of the EU and US in rollout plans of the vaccine

The European Medicines Agency (EMA) on Tuesday said it would hold an extraordinary meeting on December 29 "at the latest" to consider emergency approval for a Covid-19 vaccine developed by Germany's BioNTech and US giant Pfizer.

Pfizer said its COVID-19 vaccine, developed in association with the German partner BioNTech SE, was more than 90 per cent effective against SARS-CoV-2.

Covid vaccine makers BioNTech and Pfizer said Wednesday they would produce their jab in South Africa from 2022, a first for the continent that could see much-needed immunisation drives pick up speed.

Pfizer/BioNTech's coronavirus vaccine offers more protection than earlier thought with effectiveness in preventing symptomatic disease reaching 97 percent, according to real-world evidence published Thursday by the pharmaceutical companies.

Britain has used an emergency approval process to jump ahead of the EU and US in rollout plans of the vaccine

The European Medicines Agency (EMA) on Tuesday said it would hold an extraordinary meeting on December 29 "at the latest" to consider emergency approval for a Covid-19 vaccine developed by Germany's BioNTech and US giant Pfizer.

Pfizer said its COVID-19 vaccine, developed in association with the German partner BioNTech SE, was more than 90 per cent effective against SARS-CoV-2.